Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.62 |
| ▸ | CACNA1H | O95180 | 8/20 | 0.59 |
| ▸ | CNR2 | P34972 | 3/20 | 0.59 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3036757 | 0.88 | CACNA1I (0.76) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL3041292 | 0.88 | CACNA1I (0.76) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL2137512 | 0.86 | NR1H4 (0.45) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL2137503 | 0.86 | NR1H4 (0.45) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL2137529 | 0.82 | CACNA1I (0.50) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL2137544 | 0.82 | CACNA1I (0.50) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL1060457 | 0.80 | CACNA1I (0.82) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL12999615 | 0.80 | CACNA1I (0.52) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL4370770 | 0.79 | CACNA1I (0.77) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 | |
| SCHEMBL1063317 | 0.79 | CACNA1I (0.77) | CACNA1ICACNA1HCNR2CACNA1GKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | PRAXIS PREC MEDICINES INC (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128537-A1 | T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1H 2/4885CNR2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.